Mineralys Therapeutics, Inc. MLYS Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value?
- Mineralys Therapeutics, Inc. (MLYS) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value of $32.3M in Q4 2025.